For example, in the United States, a recent Markov simulation model of population-wide screening for CKD, which included appropriate SGLT2i treatment added to standard of care ACE inhibitors or angiotensin receptor blockers for adults age 35–75 years old with albuminuria, concluded that screening to identify CKD would be cost-effective [46]. Here, ACE is linked to chronic kidney disease.